EV3: The Missing Link Between FDA Approval and a Paid Claim

The ev3 false claims case alleged that Onyx won FDA approval for a narrow use while sales quotas counted on off-label business, and that defective Axium coils kept shipping. The allegations put patients and taxpayer-funded care at the center of decisions made in sales, training and manufacturing.

ev3 manufactured and marketed medical devices. Micro Therapeutics developed Onyx and Axium before becoming part of ev3. Onyx is a liquid injected into blood vessels to block blood flow before brain surgery. Axium is a detachable coil used to create a blockage at a selected location. A former sales representative brought the qui tam case under the False Claims Act, alleging that the companies’ conduct caused hospitals and physicians to seek improper government payments.

Onyx Approval and the Sales Business Behind It

The Onyx allegations concerned a narrow use presented to the FDA and a broader business allegedly pursued afterward. The Food and Drug Administration approved Onyx in July 2005 for treatment of brain arteriovenous malformations before surgery. The application described using it to reduce blood loss and shrink the malformation before the operation.

According to the court’s account of the proposed complaint, Micro Therapeutics emphasized physician training when seeking approval. The promised program included instruction, hands-on work, case review, observation and help from an experienced proctor for a physician’s first use. The whistleblower alleged that the companies later shortened training and used proctored procedures to teach off-label applications.

He also alleged that ev3 certified a hospital site if a trained neurosurgeon had privileges there, then supplied Onyx to the site, where other physicians could use it. Sales quotas allegedly anticipated off-label business. He alleged that sales representatives learned applications outside the brain, and physicians received off-label training at company-paid retreats.

The district court’s account explains why sales outside the brain paid so well. The larger vascular openings below the neck required more Onyx to block them, making those off-label uses more lucrative. That gave the company a reason to sell beyond the narrow approved use.

The territory figures put a number on the alleged mismatch. For one territory in 2009, the proposed complaint put ev3’s assessment of the entire on-label sales opportunity at $506,250. The assigned quota was $1,509,533. Even winning every on-label sale would have left the representative short of the target. The alleged sales plan required business beyond the use presented for approval.

The safety allegation concerned the material itself. The whistleblower alleged that Micro Therapeutics withheld critical information about failures involving Enteryx, another device made with the same molecule. These were allegations about what the FDA heard before approval, alongside allegations about what ev3 sold afterward. The court examined how each was supposed to have caused government payment.

FDA Approval and the Government Payment

The civil case ended in dismissal. In its December 2016 decision, the First Circuit found the proposed complaint did not connect the alleged deception to an FDA approval the agency otherwise would have refused.

The payment came from a different agency. The FDA decided whether Onyx could be marketed. The Centers for Medicare and Medicaid Services reimbursed physicians for procedures using it and hospitals where those procedures took place. The whistleblower’s theory ran through both decisions: misleading information produced FDA approval, and that approval made the government payments possible.

The court wanted facts showing the FDA would have said no if it had heard the truth. It also pointed to continued government reimbursement after the allegations surfaced. At the time of the decision, Onyx’s approval remained in place.

The court left room for FDA action confirming that deception had caused the approval. Its ruling concerned the connection this complaint tried to make between FDA approval and government payment. Other device cases can turn on what the manufacturer actually supplied.

Physician Training and the Missing Government Claim

The separate Onyx training theory targeted procedures performed by physicians the company had not trained. The whistleblower alleged that ev3 encouraged medically unnecessary and dangerous use by those physicians, causing false government claims.

Onyx’s label called for physicians with neurointerventional training and directed readers to the manufacturer for information about courses. The court distinguished the physician’s qualifications from attendance at the company’s own program. The proposed complaint identified physicians who missed that program without establishing that they lacked the training the label required.

The payment allegations had a similar gap. The whistleblower relied on the physicians’ use of Onyx and the share of their overall patient populations covered by government health care programs. The court found no adequate connection to patients who actually received the relevant procedures and generated government claims.

Axium Defects and What Happened in the Operating Room

The Axium allegations concerned manufacturing failures and design changes, followed by a broad claim that reimbursement involving the devices was false. The courts looked for evidence connecting the affected products to actual government claims.

The district opinion describes alleged failures of the coil to detach. According to the proposed complaint, engineering staff attributed some failures to excessive welding heat. Other alleged problems included a malformed retainer ring caused by worn manufacturing equipment and a welding error that attached a detachment wire to the coil’s inner wall.

The whistleblower also alleged that management told sales staff to emphasize manual methods for overcoming detachment failures while avoiding references to tools that might attract FDA attention. He alleged that adverse-event investigations minimized the device’s role and that required reports went unfiled.

Those details place the alleged conduct in engineering, sales and quality functions. The First Circuit found that the complaint described problems in certain lots but did not connect the affected products to particular false claims paid by the government.

The court also focused on when the problem appeared. The alleged Axium failures occurred while surgeons were trying to deploy the coil, before a reimbursement claim would have been submitted. The comparison with a hidden defect matters because a provider might bill without knowing the implanted product was defective.

Hidden Defects in the Product Shipped

The product actually supplied was central to a later case against DePuy Orthopaedics involving Pinnacle hip devices. In its 2017 decision, the First Circuit allowed allegations to proceed that the company supplied devices with hidden defects that materially departed from cleared specifications. Those alleged defects would not have appeared during surgery, and unsuspecting providers sought government reimbursement.

The case later ended in dismissal, without a decision on those device-quality allegations. The comparison concerns the product: the authorized design, the unit actually shipped and the defect hidden when the provider billed for care.

How Does Reimbursement Work for Medical Devices?

Medicare usually pays hospitals for the procedure or stay, with the implanted device’s cost included in that payment. The district court described this arrangement in the ev3 case: the hospital recovered device costs through aggregate reimbursement rates. The manufacturer’s sale to a hospital and the hospital’s government claim were different transactions.

The physician may make or strongly influence the device choice, while the hospital purchases the product. The Department of Health and Human Services’ Inspector General describes implantable devices as physician preference items for that reason. A sales representative may know why a surgeon selected a product while the provider’s records show its use and billing.

In hospital outpatient billing, device codes and charges can appear even when the device cost is included in the procedure’s payment. FDA authorization, Medicare coverage and the amount paid remain separate decisions in that healthcare transaction.

There is another practical separation: an ordinary hospital claim does not identify the implanted product by its unique device identifier. A payment record can show the procedure while the model and lot remain in the hospital’s product and clinical records. That is why someone who understands the device can contribute information the bill alone leaves invisible.

What Evidence Is Needed to Prove Fraud?

The evidence in a device fraud case connects what happened inside the manufacturer to the care billed to the government. We work with insiders to follow that connection across sales, clinical work and product quality.

Reporting decisions show how the company described a problem. Manufacturers receive much of the adverse-event information from facilities and importers and evaluate reportable malfunctions. The internal complaint and testing files can show what the company learned and how it characterized a failure.

A separate whistleblower complaint against Therakos alleged a more concrete change to how sales activity was recorded:

That allegation concerns the company’s control over the account its own salespeople could leave behind. The database design itself was part of the alleged effort to keep off-label promotion out of the sales record.

The Connection You Can See Inside the Company

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. Speak to our whistleblower experts about what your sales, clinical or quality work reveals about the devices used in government-funded care. We work with you to build your strongest medical device whistleblower case, bring in medical device whistleblower lawyers who understand FDA records and reimbursement, and stay beside you throughout the case.